US20070148151A1 - Processes for the manufacture and use of pancreatin - Google Patents

Processes for the manufacture and use of pancreatin Download PDF

Info

Publication number
US20070148151A1
US20070148151A1 US11/460,330 US46033006A US2007148151A1 US 20070148151 A1 US20070148151 A1 US 20070148151A1 US 46033006 A US46033006 A US 46033006A US 2007148151 A1 US2007148151 A1 US 2007148151A1
Authority
US
United States
Prior art keywords
pancreatin
heating
solvents
hours
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/460,330
Other languages
English (en)
Inventor
Martin Frink
Claus-Juergen Koelln
Heinz Blume
Michael Rust
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Products GmbH
Original Assignee
Solvay Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20070148151(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Solvay Pharmaceuticals GmbH filed Critical Solvay Pharmaceuticals GmbH
Priority to US11/460,330 priority Critical patent/US20070148151A1/en
Assigned to SOLVAY PHARMACEUTICALS GMBH reassignment SOLVAY PHARMACEUTICALS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FRINK, MARTIN, BLUME, HEINZ, RUST, MICHAEL, KOELLN, CLAUS-JUERGEN
Publication of US20070148151A1 publication Critical patent/US20070148151A1/en
Assigned to ABBOTT PRODUCTS GMBH reassignment ABBOTT PRODUCTS GMBH CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SOLVAY PHARMACEUTICALS GMBH
Priority to US15/214,973 priority patent/US10704037B2/en
Priority to US16/893,036 priority patent/US20200299669A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/94—Pancreatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • pancreatin Described herein is a process for the manufacture and use of pancreatin in which the concentration of one or more viral contaminants therein is reduced by heating the pancreatin.
  • Pancreatin is a substance which is derived from mammalian pancreas glands and comprises different digestive enzymes such as lipases, amylases and proteases. Pancreatin has been used to treat pancreatic exocrine insufficiency which is often associated with cystic fibrosis, chronic pancreatitis, post-pancreatectomy, post-gastrointestinal bypass surgery (e.g. Billroth II gastroenterostomy) and ductal obstruction from neoplasm (e.g. of the pancreas or common bile duct). For the application of pancreatin in pharmacological products it is preferred to substantially maintain the intrinsic high level of activity of the different digestive enzymes. However, these enzymes can be subject to degradation, e.g., upon storage, and are particularly sensitive to elevated temperatures. Thus, pancreatin requires carefully controlled conditions during the overall handling, manufacturing and storage process.
  • pancreatin requires carefully controlled conditions during the overall handling, manufacturing and storage process.
  • pancreatin Due to the animal origin of pancreatin, this may further comprise other components which are unwanted such as one or more biological contaminants.
  • these may further comprise other components which are unwanted such as one or more biological contaminants.
  • pancreatin contaminated by any virus.
  • companies producing pharmaceutical products derived from biological tissues and/or body fluids experience increasing pressure from the regulatory bodies to increase the level of safety of their products by reducing all kinds of contaminants to the lowest level possible, independent of whether any concerned contaminant is considered a human pathogen or not.
  • pancreatin for the manufacturing, handling and storage process of pancreatin, the skilled person is faced with the challenge of tailoring such processes in a way that a high level of activity of the different digestive enzymes is maintained while at the same time the concentration of one or more biological contaminants therein is minimized.
  • pancreatin The current manufacturing processes of pancreatin would not seem to allow efficient inactivation of biological contaminants, in particular of specific viruses.
  • Heat treatment implies that the product e.g. be heated to 60° C. for 70 hours which can be damaging to sensitive products. In some instances, conventional heat inactivation can actually destroy a substantial amount of the enzymatic activity of a product.
  • Filtration involves filtering the product in order to physically remove contaminants. Unfortunately, this method may also remove products having a high molecular weight. Further, in certain cases, small viruses and similarly sized contaminants and pathogens may not be removed by the filter.
  • the procedure of chemical sensitization involves the addition of noxious agents which bind to the DNA/RNA of the virus and which are activated by either UV or other radiation.
  • the radiation produces reactive intermediates and/or free radicals which bind to the DNA/RNA of the virus, break the chemical bonds in the backbone of the DNA/RNA, and/or crosslink or complex it in such a way that the virus can no longer replicate.
  • This procedure requires unbound sensitizer to be washed from products since the sensitizers are toxic, if not mutagenic or carcinogenic, and cannot be administered to a patient.
  • U.S. Pat. No. 3,956,483 discloses a method of preparing pancreatin having suitable amylolytic, proteolytic and lipolytic activities and of eliminating harmful bacteria therefrom while maintaining said activities. Said method comprises heating the pancreatin to a sufficiently high temperature between 120° F. and 180° F. (approx. 49-82° C.). Lewis, however, fails to provide a process which would be suitable to minimize the concentration of viruses down to presently accepted detection limits.
  • U.S. Pat. No. 6,749,851 suggests the treatment of compositions comprising digestive enzymes by stabilizing the compositions in a first step by either (a) reducing the temperature of, (b) reducing the solvents of, or (c) adding a stabilizer to the composition, followed by irradiation of the composition in a second step.
  • Braeuniger et al. (Braeuniger et al., Int. J. Hyg. Environ. Health 203, 71-75, 2000) suggest the use of heat for the inactivation of the bovine parvovirus. It has been demonstrated that the bovine parvovirus which can be deactivated is dependent upon exposure and residual moisture. In general, higher moisture contents allow shorter heat exposure durations providing the same inactivation as a lower moisture content in combination with a longer exposure duration. However, Braeuniger et al. do not disclose anything about the effect that heat has on enzymes such as lipases, amylases and proteases forming part of animal pancreatin. Thus, there is a need for a process which provides pancreatin having enzymes with a high level of activity while sufficiently reducing the concentration of biological contaminants.
  • pancreatin in which the concentration of one or more biological contaminants therein has been reduced and in which the enzyme activity is maintained at an acceptable level.
  • a process as disclosed and claimed herein is useful to decrease the concentration of viral contaminants in pancreatin.
  • the process described herein has been found to effectively meet various regulatory requirements regarding the removal of viruses from biological products (e.g.
  • pancreatin Another advantage of the process described herein, and the resulting pancreatin, as well as the pharmaceutical compositions comprising the pancreatin obtained by the process described herein, is its applicability for laboratory scale, pilot scale and production scale.
  • one embodiment disclosed herein is a process for the manufacture of pancreatin in which the concentration of one or more biological contaminants, in particular of viral contaminants, has been reduced by heating the pancreatin for a period up to about 48 hours at a temperature of at least 85° C. wherein the solvents in the pancreatin are less than about 9% by weight at any point during the heating step.
  • Such process provides pancreatin, in which the enzyme activity is maintained at an acceptable level and in which the concentrations of one or more biological contaminants, in particular of one or more viral contaminants, are reduced.
  • Described herein is a process for the manufacture of pancreatin, comprising heating a dispersed form of pancreatin containing one or more solvents at a temperature of at least 85° C. for a period of up to about 48 hours, and wherein the total amount of solvents present in the pancreatin is less than about 9% by weight at any point during the heating step.
  • Another embodiment disclosed herein is a process for manufacturing a pharmaceutical composition comprising pancreatin, in accordance with the disclosed process wherein such pharmaceutical composition is in a dosage form suitable for oral administration and for immediate and/or modified release, such dosage form can be selected from tablets, microtablets, pellets, micropellets, microspheres, granules, granulates, powders, suspensions, emulsions, dispersions, capsules, sachets as well as other dosage forms.
  • Another embodiment is directed to a pharmaceutical composition in the form of a capsule or sachet wherein the capsule or sachet comprises pancreatin subjected to the disclosed process.
  • Another embodiment is directed towards a method of treating pancreatic exocrine insufficiency by administering a safe and effective amount of pancreatin obtained by the process described herein.
  • FIG. 1 Lipase activity after heating pancreatin at temperatures of 80° C., 85° C., 90° C., 95° C. and 100° C. with a solvent content of 1%. The lipase activity was determined after 2, 4, 6, 12, 15, 18, 21, 24 and 30 hours.
  • FIG. 2 Lipase activity after heating pancreatin at temperatures of 90° C. and 95° C. with a solvents content of 3%. The lipase activity was determined after 2, 4, 8, 15, 24 and 48 hours.
  • FIG. 3 Lipase activity after heating pancreatin at a temperature of 80° C. having a solvent content of 3%, 6%, 9% and 12%. The lipase activity was determined after 0.5, 1.0 and 3.0 hours.
  • FIG. 4 Log titer reduction of porcine pancreatin spiked with porcine parvovirus (hereinafter referred to as “PPV-spiked pancreatin”) at temperatures of 80° C., 85° C., 90° C., 95° C. and 100° C. having a solvent content of 1 %.
  • the virus concentration was determined after 6, 12, 15, 18, 21, 24 and 30 hours.
  • FIG. 5 Log titer reduction of PPV-spiked pancreatin at temperatures of 90° C. and 95° C. having a solvent content of 1 % and 3% for a period of 12 hours. The virus concentration was determined after 3, 6 and 12 hours.
  • the term “sterilize” is intended to mean a reduction in the concentration of at least one biological contaminant found in pancreatin, in particular dispersed pancreatin, being subjected to the process described herein. More specifically, the term “sterilize” is intended to mean a reduction in the concentration of at least one viral contaminant found in pancreatin, in particular dispersed pancreatin, being subjected to the process described herein.
  • pancreatin is intended to mean pancreatin originating from any mammalian pancreas glands, such as bovine and porcine pancreatins.
  • pancreatin which is produced according to the processes described in U.S. Pat. No. 4,623,624 or according to analogous processes may be used for the purposes of the present disclosure.
  • Dispersed forms of pancreatin comprise e.g. powders, pellets, micropellets, microspheres, granules and granulates.
  • pancreatin powders e.g. pancreatin powders directly obtained from a process to produce pancreatin.
  • the pancreatin as used herein may also comprise one or more pharmaceutically acceptable excipients which are compatible with the process conditions as described herein and which may be e.g. selected from the pharmaceutically acceptable excipients provided below.
  • biological contaminant(s) is intended to mean a contaminant that, upon direct or indirect contact with pancreatin, may have a deleterious effect on the pancreatin or upon a recipient thereof.
  • active biological contaminant is intended to mean a biological contaminant that is capable of causing a deleterious effect, either alone or in combination with another factor, such as a second biological contaminant, in the preparation of pancreatin or to the recipient of the pancreatin.
  • biological contaminants include, but are not limited to, viral contaminants and/or germs.
  • Germs include, but are not limited to, bacteria, molds and/or yeasts.
  • a biological contaminant may be a human pathogen.
  • virus or “viral contaminant(s)” is intended to mean particularly non-enveloped viruses. More specifically, the term “virus” or “viral contaminant(s)” includes so-called highly resistant viruses like the parvoviridae, in particular the porcine parvoviridae, the circoviridae, in particular the porcine circoviridae, and the caliciviridae, in particular the porcine caliciviridae.
  • the porcine parvovirus (PPV) may serve as a generally accepted model or indicator virus for the whole class of highly resistant viruses, in particular highly resistant porcine viruses.
  • virus or “viral contaminant(s)” in the context of the present disclosure also includes the picornaviridae, in particular the porcine picornaviridae, the reoviridae, in particular the porcine reoviridae, the astroviridae, in particular the porcine astroviridae the adenoviridae, in particular the porcine adenoviridae and the hepeviridae, in particular the porcine hepeviridae.
  • the term “virus” or “viral contaminant(s)” in the context of the present disclosure also includes the picornaviridae, in particular the porcine picornaviridae, the reoviridae, in particular the porcine reoviridae, the astroviridae, in particular the porcine astroviridae the adenoviridae, in particular the porcine adenoviridae and the hepeviridae, in particular the porcine hepeviridae.
  • solvent or “solvents” is intended to mean the amount or proportion of liqiud which is present in the pancreatin, either as bound or complexed liquid or as freely available liquid in the pancreatin.
  • Freely available liquid means the liquid present in the pancreatin being heated that is not bound to or not complexed with the pancreatin.
  • Said liquids present in the pancreatin usually comprise water and enzyme friendly organic solvents and mixtures of water with said enzyme friendly organic solvents.
  • Suitable enzyme friendly organic solvents are usually volatile organic solvents like e.g.
  • acetone, chloroform, dichloromethane or straight-chained or branched C 1-4 -alcanols particularly methanol, ethanol, 1-propanol, 2-propanol, 2-butanol, tert.-butanol or mixtures of said solvents.
  • 2-propanol is preferred as enzyme friendly organic solvent.
  • the ratio of water to enzyme friendly organic solvent is between 50:1 and 3:1, more typically between 30:1 and 10:1.
  • a temperature range e.g. of from 85° C. to about 100° C.
  • it is intended to mean a temperature anywhere within the expressly mentioned range as well as a temperature profile leading to different temperatures within the expressly mentioned range.
  • the temperature range during the process as disclosed herein can be applied continuously or discontinuously, as long as the overall periods of time within the disclosed temperature ranges are met.
  • the process described herein comprises heating the pancreatin for a period up to about 48 hours at a temperature of at least 85° C. wherein the total amount of solvents present in the pancreatin is less than about 9% by weight at any point during the heating step.
  • the solvents content of the pancreatin is typically less than about 8%, even more typically less than about 6%, usually less than about 5%, mostly less than about 3.5%, preferably from about 0.1% to about 3.5%, more preferably from about 0.1% to about 3% and even more preferably from about 0.1% to about 1.6% by weight. In other embodiments, the solvent content is less than about 7.5%, 7.0%, 6.5%, 6.0%, 5.5%, 5.0%, 4.5%, 4.0%, 3.5%, 3.0%, 2.5%, 2.0%, 1.5%, 1.0%, or 0.5%.
  • the process described herein uses a dispersed pancreatin, in particular a pancreatin powder, with an initial solvents content of about 9% by weight or less, typically between about 2% and about 3.5% by weight.
  • the pancreatin is then heated to the desired process temperature which may be from 85° C. to about 100° C., e.g. 90° C.
  • the solvents content in the pancreatin will typically decrease as a function of time and temperature. It is to be understood that the duration of said initial heat-up phase is a function of batch-size and initial batch temperature and therefore may take between approximately 15 minutes and as long as about 10 hours.
  • the pancreatin is heated at a temperature of at least 85° C., usually within the range of 85° C. to about 100° C., e.g. about 90° C., and for the disclosed process time, i.e. for a period of up to about 48 hours, e.g. for a period of 24 hours.
  • the solvents content reached at the end of the heat-up phase can typically be found to be from about 0.1% to about 1.6% by weight. It can be observed that the solvents content of about 0.1% to about 1.6% by weight reached at the end of the heat-up phase will be relatively constant over the entire range of the preferred process parameters.
  • the heated pancreatin may again be exposed to normal ambient conditions (e.g. room temperature and normal moisture conditions).
  • normal ambient conditions e.g. room temperature and normal moisture conditions.
  • the pancreatin is heated for a period of from about 1 hour to about 36 hours, more preferred for a period of from about 8 hours to about 30 hours, yet more preferred for a period of from about 10 hours to about 24 hours.
  • the dispersed pancreatin is heated for a period of from about 1 hour to about 36 hours, such as, e.g., about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, 25 hours, 26 hours, 27 hours, 28 hours, 29 hours, 30 hours, 31 hours, 32 hours, 33 hours, 34 hours, 35 hours, or 36 hours, and in another embodiment of such process, the dispersed pancreatin is heated for a period of from about 10 hours to about 30 hours.
  • the pancreatin is heated at a temperature of from 85° C. to about 100° C., specifically at a temperature of 85° C., 86° C., 87° C., 88° C., 89° C., 90° C., 91° C., 92° C., 93° C., 94° C., 95° C., 96° C., 97° C., 98° C., 99° C., 100° C., or any temperature in the ranges between these given integer temperature values.
  • the pancreatin is heated at a temperature of from 85° C.
  • the pancreatin is heated at a temperature of from about 90° C.
  • the pancreatin is heated at a temperature of from about 90° C. to about 95° C., specifically at a temperature of 90° C., 91° C., 92° C., 93° C., 94° C., 95° C., 96° C., 97° C., 98° C., 99° C., 100° C., or any temperature in the ranges between these given integer temperature values.
  • the pancreatin is heated at a temperature of from about 90° C. to about 95° C., specifically at a temperature of 90° C., 91° C., 92° C., 93° C., 94° C., 95° C. or any temperature in the ranges between these given integer temperature values.
  • the solvents content of the pancreatin is from about 0.1% to about 3.5% by weight and the pancreatin is heated for a period of from about 8 hours to about 30 hours at a temperature of from 85° C. to about 100° C.
  • the solvents content of the pancreatin is from about 0.1% to about 3.0% by weight and the pancreatin is heated for a period of from about 10 hours to about 30 hours at a temperature of from 85° C. to about 95° C.
  • the solvents content of the pancreatin is from about 0.1 % to about 1.6% by weight and the pancreatin is heated for a period of from about 10 hours to about 30 hours at a temperature of from 85° C. to about 95° C.
  • the concentration of one or more biological contaminants in the pancreatin is decreased, in particular the concentration of one or more viral contaminants, without substantially affecting the activity of the pancreatin.
  • the concentration of highly resistant viruses in the pancreatin is decreased.
  • pancreatin obtainable by the process described herein. All provisions made above for the process described herein are also applicable for the pancreatin obtainable by such process.
  • Another embodiment is directed to a process for manufacturing a pharmaceutical composition comprising pancreatin in accordance with the process described herein wherein such pharmaceutical composition is in a dosage form suitable for oral administration.
  • the oral dosage form can be for immediate and/or modified release, such dosage form can be tablets, microtablets, pellets, micropellets, microspheres, granules, granulates, powders, suspensions, emulsions, dispersions, capsules sachets as well as other dosage forms.
  • the pancreatin and/or its dosage form is further coated with a gastric acid resistant coating.
  • the optionally gastric acid resistant coated pancreatin or its dosage form is further filled into sachets and/or capsules.
  • Described herein is a pharmaceutical composition
  • a pharmaceutical composition comprising
  • the pancreatin is present in a dosage form which is suitable for oral administration.
  • the oral dosage form can be for immediate and/or modified release, such dosage form can be tablets, microtablets, pellets, micropellets, microspheres, granules, granulates, powders, suspensions, emulsions, dispersions, capsules, sachets, as well as other dosage forms.
  • pancreatin and/or the pharmaceutically acceptable excipients are further coated with a gastric acid resistant coating.
  • compositions in the form of a capsule or sachet, the capsule or sachet comprising the pancreatin described herein.
  • composition further comprises pharmaceutically acceptable excipients.
  • the composition is in a dosage form suitable for oral administration.
  • the oral dosage form can be for immediate and/or modified release, such dosage form can be tablets, microtablets, pellets, micropellets, microspheres, granules, granulates, powders, suspensions, emulsions, dispersions, capsules, sachets as well as other known dosage forms.
  • pancreatin and/or the pharmaceutically acceptable excipients and/or its dosage form is further coated with a gastric acid resistant coating.
  • compositions described herein may comprise pharmaceutically acceptable excipients.
  • Pharmaceutically acceptable excipients for use in the compositions described above are exemplified by: sugars such as lactose, sucrose, mannitol and sorbitol; starches such as cornstarch, tapioca starch and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; calcium phosphates such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone; polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate; stearic acid; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil and corn oil; non-ionic, cationic and anionic surfactants; ethylene glycol polymers; betacyclodextrin; fatty alcohols
  • a pharmaceutical composition according to the invention may comprise about 0.1% to about 100%, such as, e.g., about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, preferably of from about 25% to about 90%, such as, e.g., 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%, more preferably from about 50% to about 90%, such as, e.g., 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90% by weight, of pancreatin and the remaining proportions, if any, being made up by pharmaceutically acceptable auxiliaries, excipients and/or carriers.
  • the pharmaceutical compositions comprise (a) from about 50% to about 90% by weight of pancreatin obtained by the process described herein, and (b) from about 10% to about 50% by weight, of pharmaceutically acceptable excipients, e.g. ethylene glycol polymers, in particular ethylene glycol 2000, 3000, 4000, 6000, 8000 and/or 10000.
  • pharmaceutically acceptable excipients e.g. ethylene glycol polymers, in particular ethylene glycol 2000, 3000, 4000, 6000, 8000 and/or 10000.
  • the pharmaceutical compositions comprise (a) from about 55% to about 85% by weight of pancreatin obtained by the process described herein, (b) from about 5% to about 35% by weight of ethylene glycol polymers, (c) from about 1.0% to about 20% by weight of propan-2-ol, and (d) optionally from 0% to about 10% by weight of paraffin.
  • Other compositions comprising pancreatin are e.g. disclosed in EP 0 583 726 and in EP 0 826 375.
  • the processes described herein may be carried out at any temperature of at least 85° C. which does not result in an unacceptable level of damage to the pancreatin.
  • an “acceptable level” of damage may vary depending upon certain features of the particular processes described herein being employed, such as the nature and characteristics of the particular pancreatin being used, and/or the intended use of the pancreatin being heated, and can be determined empirically by one skilled in the art.
  • An “unacceptable level” of damage would therefore be a level of damage that would preclude the safe and/or effective use of the pancreatin being heated.
  • the particular level of damage to a given pancreatin sample may be determined using any of the methods and techniques known to one skilled in the art.
  • a residual enzyme activity after heating of 50% or more, preferably about 70% or more, more preferably about 85% or more and most preferably about 90% or more, of the original enzyme activity is desirable.
  • the virus titers were calculated as mentioned above and these are presented as log 10 TCID 50 per ml with 95% confidence limits.
  • the capacity of the treatment to deactivate or remove viruses was described by means of the logarithmic reduction factors (LRF).
  • LRF logarithmic reduction factors
  • a decrease in the concentration of biological contaminants therein in particular a decrease in the concentration of viral contaminants, of at least about 3.0, preferably about 3.5, more preferably about 4.0 and most preferably about 4.5 or more log titer reductions is desirable.
  • a process which can provide 4.0 log titer reductions is usually considered robust in terms of virus deactivation and therefore deemed satisfactory.
  • a process for sterilizing pancreatin can be said to be most effective if application of this process results in a satisfactory decrease of even highly resistant viruses in the pancreatin.
  • lipase activity decreases as incubation time increases at a given temperature. Furthermore, the lipase activity declines to a greater extent at high temperatures at a given incubation time.
  • heating conducted for a period of up to and including 30 hours at temperatures up to and including 95° C. provide pancreatin having acceptable residual enzyme activity at a solvents content of 1%.
  • heating conducted for a period of up to and including 24 hours at temperatures up to and including 100° C. provide pancreatin having acceptable residual enzyme activity at a solvents ontent of 1%.
  • the lipase activity decreases as incubation time increases at a given temperature. Furthermore, the lipase activity declines to a greater extent at high temperatures at a given incubation time.
  • heating conducted for a period of up to and including 48 hours at temperatures up to and including 90° C. provide pancreatin having acceptable residual enzyme activity at a solvents content of 3%.
  • heating conducted for a period of up to and including 24 hours at temperatures up to and including 95° C. provide pancreatin having acceptable residual enzyme activity at a solvents content of 3%.
  • the lipase activity decreases as incubation time increases at 80° C. Furthermore, the lipase activity declines to a greater extent at high solvents contents at a given incubation time.
  • heating conducted for a period of up to and including 3 hours at a temperature of 80° C. provide pancreatin having acceptable residual enzyme activity at a solvents content of 6%.
  • heating conducted for a period of up to and including 1 hour at a temperature of 80° C. provide pancreatin having acceptable residual enzyme activity at a solvents content of 9%.
  • pancreatin powder batches 2 to 4 were prepared and processed at 85° C. as described above in table 4 and below in Example 13.
  • the log 10 TCID 50 after heating for 6, 12, 15, 18, 21, 24 and 30 hours at 85° C. were determined at a constant solvent content of 1% .
  • Table 5 shows the log titer reduction in comparison to the beginning of the experiment.
  • FIG. 4 illustrates the log titer reduction of PPV-spiked pancreatin after heating at 80° C., 85° C., 90° C., 95° C. and 100° C. with a solvents content of 1%.
  • the log titer reduction increases as incubation time increases at a given temperature. Furthermore, the log titer reduction declines to a greater extent as temperature increases.
  • heating conducted for a period of up to and including 30 hours at a temperature of 80° C. provide pancreatin having an acceptable decrease in the concentration of biological contaminants therein at a solvents content of 1%.
  • Experiments conducted for a period of 12 hours and at a temperature of 90° C. provide pancreatin having a decrease in the concentration of biological contaminants therein at a solvents content of 1%.
  • Experiments conducted for a period of 15 hours and at a temperature of 90° C. provide pancreatin having an even larger decrease in the concentration of biological contaminants therein at a solvents content of 1%.
  • Table 7 shows the log titer reduction (for the results as presented in table 5) in porcine parvovirus relative to the initial amount.
  • FIG. 5 illustrates the log titer reduction of PPV-spiked pancreatin after heating at 90° C. and 95° C. with a solvents content of 1% and 3%, respectively.
  • the experiments leading to the results as presented in tables 6 and 7 were performed under slightly different conditions compared with the experiments leading to the results as presented in table 5.
  • TABLE 7 Log Titer reduction after heating of PPV-spiked pancreatin at 90° C. and 95° C. with a solvents content of 1% and 3%, respectively.
  • the concentration of porcine parvovirus can be effectively reduced by heating under the conditions set forth above. It can be concluded from the above experiments that the reduction is more effective at high temperatures and/or over a long period of time and/or at higher solvents content.
  • the concentration of the porcine parvovirus can be effectively reduced if the virus is heated at a suitably elevated temperature and solvents contents over a sufficient period of time.
  • the steps of adjusting the solvents content and heating may occur at any pressure which is not deleterious to the pancreatin being heated.
  • the disclosed processes are conducted at atmospheric, reduced or elevated pressure. Suitable pressures can be determined empirically by one skilled in the art.
  • the processes are conducted at atmospheric or reduced pressure.
  • the processes are conducted at atmospheric pressure.
  • the processes described herein are conducted under vacuum while being sterilized.
  • heating may occur under any atmosphere that is not deleterious to the pancreatin being treated.
  • the processes described herein are conducted in standard atmosphere.
  • the disclosed processes are conducted in a low oxygen atmosphere or an inert atmosphere.
  • the atmosphere is preferably composed of nitrogen or a noble gas, such as helium or argon, more preferably a higher molecular weight noble gas, and most preferably argon. It will be appreciated that the combination of one or more of the features described herein may be employed to further minimize undesirable effects upon the processes described herein, while maintaining adequate effectiveness of the processes on the biological contaminant(s).
  • the solvents content of pancreatin may be reduced by any of the methods and techniques known to those skilled in the art for reducing solvent from a preparation of one or more digestive enzymes without producing an unacceptable level of damage to the preparation.
  • Such methods include, but are not limited to, evaporation, concentration, centrifugal concentration, vitrification, addition of solute, lyophilization (with or without the prior addition of ascorbate) and spray-drying.
  • a preferred method for reducing the solvents content of pancreatin is concentration, which may be accomplished by any of the methods and techniques known to those skilled in the art. Concentration may be achieved either by controlled heating of the preparation and subsequent evaporation of the unwanted solvent or by evaporation via reduced pressure. Also a combination of these two methods under mild conditions, evaporation at low temperature under reduced pressure, may be applied in order to achieve the desired solvents content. Regardless of the method used, the resulting preparation will then have the desired solvents content.
  • the processes described herein may be conducted at any scale, at laboratory scale with preparations having a mass from 1 g to 1000 g; at pilot plant scale with preparations having a mass from 1 kg to 50 kg and a production scale with preparations having a mass from at least 100 kg, preferably from 200 kg to 1500 kg.
  • the determination of the lipase activity was performed according to a Solvay testing method which is based on the monograph of pancreas powder in Ph. Eur. (Pancreas Powder, European Pharmacopoeia 5.0, 2179-2182; 01/2005:0350).
  • the solvents contents related as water referenced herein refer to levels determined by the FDA approved, modified Karl Fischer method (Meyer and Boyd, Analytical Chem., 31:215-219, 1959; May, et al., J. Biol. Standardization, 10:249-259, 1982; Centers for Biologics Evaluation and Research, FDA, Docket No. 89D-0140, 83-93; 1990). Quantitation of the contents of other solvents may be determined by means known to those of skill in the art, depending on which solvent is employed. Further suitable means for determining solvent contents in the pancreatin during or after the process disclosed herein, which are also included in the present disclosure, are e.g.
  • thermogravimetric methods including infrared drying and microwave drying
  • spectrometric methods including infrared spectroscopy, microwave spectroscopy and nuclear magnetic resonance spectroscopy
  • conductometry decametry
  • thermal conduction e.g. the preferred method for determining the solvents contents in pancreatin is a thermogravimetric method (e.g. determination of “loss on drying”), since this method would cover all liquids which may be present in the pancreatin, comprising e.g. water and enzyme friendly organic solvents like isopropanol.
  • Thermogravimetric methods are in particular suited for measuring solvents contents of about 9% -3.5% by weight in the pancreatin.
  • solvents contents are to be determined in the pancreatin, e.g. solvents contents below about 3.5%, more typically of less than 3%, even more typically of less than 1.6% by weight
  • the proportion of water present in the solvents content of pancreatin will typically outweigh the proportion of enzyme friendly organic solvent present in the pancreatin. It may therefore be advantageous to measure solvents contents below about 3.5%, more typically of less than 3%, even more typically of less than 1.6% by weight by using the more sensitive Karl Fischer method or a modification thereof.
  • infrared spectroscopic determination of the solvent contents is advantageous, in particular where solvents contents below about 3.5%, more typically of less than 3%, even more typically of less than 1.6% by weight are to be measures, e.g. in the steady state of the heating process after the pre-heating.
  • NIR near infrared spectroscopy determination methods
  • the infrared spectoscopic methods will typically need to be standardized against a reference method which can be the Karl-Fischer water titration method or a modification thereof.
  • the most preferred method of measuring the total solvents content in a pancreatin is a combination of a thermogravimetric method (i.e.
  • determining the loss on drying in the pancreatin, in particular for a pancreatin with a higher solvents content) with a Karl Fischer method or a modification thereof i.e. determining the remaining water content in the pancreatin, in particular for a pancreatin with a lower solvents content.
  • the virus titers within the treated samples were determined by virus endpoint titration and the TCID 50 was calculated according to the Spearman-Kaerber formula as described in the Bundesan manufacture No. 84, May 4 1994.
  • the test material was diluted by 3 log titers (e.g. 1:2000) prior to titration in each case.
  • the ability of the treatment to deactivate or remove viruses was described by means of the logarithmic reduction factors.
  • LTR logarithmic titer reduction
  • a drying oven e.g. from company Memmert, ULE 400
  • rotary evaporator e.g. from company Büchi, R-144
  • a water bath e.g. Büchi B-480
  • a vacuum dryer company: Hosokawa, Vrieco-Nauta®, volume 120 L
  • a vacuum dryer company: Hosokawa, Vrieco-Nauta®, volume 4000 L
  • pancreatin powder samples 50 kg to 1000 kg of moist pancreatin (initial solvents content 40-50%) was dried in a vacuum dryer with continuous stirring. The temperature was increased stepwise from 60° C. to 95° C. Drying was then carried out at a temperature of at least 70° C. until a solvents content of ⁇ 3.5% is reached. To obtain pancreatin powder samples of solvent contents of 6%, 9% or 12% by weight, respectively, samples may be taken at appropriate earlier points during the drying process in a known manner.
  • a solvent e.g., water, propan-2-ol or mixtures thereof
  • a solvents content e.g., water, propan-2-ol or mixtures thereof
  • pancreatin for porcine parvovirus studies:
  • pancreatin was spiked with added porcine parvovirus in order to establish proof of principle.
  • the spiking was conducted according to the guideline CPMP/BWP/268/95.
  • pancreatin powder After performing the standard drying of the production process (see above) on pancreatin, the pancreatin powder was cooled down and re-suspended in water (resulting in a 40% suspension in order to obtain a homogeneous distribution of the spiked virus within the pancreatin powder).
  • the pancreatin was then spiked with a highly concentrated porcine parvovirus suspension in cell culture medium in a ratio 9:1 (pancreatin suspension : virus suspension).
  • the resulting suspension was then lyophilized and subsequently heated at a temperature of from 80° C. to 100° C. until a solvents content of 1% and 3% by weight, respectively, was reached in accordance with the starting requirements of the experiments described below (examples 12 to 20 as below).
  • composition comprising Pancreatin
  • a composition comprising the pancreatin obtained by the process described herein is obtained as follows: 10 kg of pancreatin obtained by the process of example 2 is mixed with 2.5 kg of ethylene glycol 4000 and 1.5 kg of propan-2-ol to give a mixture which was then extruded in a known manner in an extruding press.
  • Pancreatin micropellets are prepared as disclosed in EP 0 583 726 and can be further packed into capsules or sachets.
  • the pancreatin micropellet cores obtained by example 21 can be provided with a gastric acid resistant coating.
  • Copolymers known as film-forming agents such as, for example, methacrylic acid/methyl methacrylate copolymers or methacrylic acid/ethyl acrylate copolymers, can also be used.
  • the film-forming agents can be applied to the pancreatin micropellet cores using various film-coating apparatus, e.g. coaters, in the customary use forms, e.g. as organic solutions or organic or aqueous dispersions, optionally with addition of a conventional plasticizer.
  • the resulting gastric acid-resistant film-coated pancreatin micropellets are distinguished by a high bulk density, for example in the range from 0.6 g/ml to 0.85 g/ml, which makes it possible to increase the filling weight per capsule and thus the active compound content of each capsule. Further experimental details on the process for preparing the gastric acid-resistant film-coated pancreatin micropellets are disclosed in EP 0 583 726.
  • the amount of broadening from the strict numerical boundary depends upon many factors. For example, some of the factors which may be considered include the criticality of the element and/or the effect a given amount of variation will have on the performance of the claimed subject matter, as well as other considerations known to those of skill in the art. As used herein, the use of differing amounts of significant digits for different numerical values is not meant to limit how the use of the words “about” or “approximately” will serve to broaden a particular numerical value. Thus, as a general matter, “about” or “approximately” broaden the numerical value.
  • ranges is intended as a continuous range including every value between the minimum and maximum values plus the broadening of the range afforded by the use of the term “about” or “approximately.”
  • ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it there individually recited herein.
  • any ranges, ratios and ranges of ratios that can be formed by, or derived from, any of the data disclosed herein represent further embodiments of the present disclosure and are included as part of the disclosure as though they were explicitly set forth. This includes ranges that can be formed that do or do not include a finite upper and/or lower boundary. Accordingly, a person of ordinary skill in the art most closely related to a particular range, ratio or range of ratios will appreciate that such values are unambiguously derivable from the data presented herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
US11/460,330 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin Abandoned US20070148151A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/460,330 US20070148151A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin
US15/214,973 US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin
US16/893,036 US20200299669A1 (en) 2005-07-29 2020-06-04 Processes for the Manufacture and Use of Pancreatin

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70381305P 2005-07-29 2005-07-29
EP05016533 2005-07-29
US11/460,330 US20070148151A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/214,973 Continuation US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin

Publications (1)

Publication Number Publication Date
US20070148151A1 true US20070148151A1 (en) 2007-06-28

Family

ID=35457614

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/460,330 Abandoned US20070148151A1 (en) 2005-07-29 2006-07-27 Processes for the manufacture and use of pancreatin
US15/214,973 Active US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin
US16/893,036 Abandoned US20200299669A1 (en) 2005-07-29 2020-06-04 Processes for the Manufacture and Use of Pancreatin

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/214,973 Active US10704037B2 (en) 2005-07-29 2016-07-20 Processes for the manufacture and use of pancreatin
US16/893,036 Abandoned US20200299669A1 (en) 2005-07-29 2020-06-04 Processes for the Manufacture and Use of Pancreatin

Country Status (18)

Country Link
US (3) US20070148151A1 (zh)
EP (2) EP1913138B1 (zh)
JP (1) JP5140586B2 (zh)
KR (1) KR101555058B1 (zh)
CN (1) CN101233229B (zh)
AU (1) AU2006274835B2 (zh)
BR (1) BRPI0614914A2 (zh)
CA (1) CA2616943C (zh)
ES (2) ES2635308T3 (zh)
HK (1) HK1120288A1 (zh)
HU (2) HUE031042T2 (zh)
IL (1) IL189103A (zh)
MX (1) MX2008000850A (zh)
NO (2) NO340996B1 (zh)
PL (2) PL1913138T3 (zh)
RU (1) RU2413532C2 (zh)
UA (1) UA93384C2 (zh)
WO (1) WO2007014896A1 (zh)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071683A1 (en) * 1999-12-17 2004-04-15 Fallon Joan M. Methods for treating pervasive development disorders
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US20070270976A1 (en) * 2002-04-25 2007-11-22 Ultraflex Systems, Inc. Ambulating ankle & knee joints with bidirectional dampening and assistance using elastomeric restraint
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US20080152637A1 (en) * 2000-08-14 2008-06-26 Fallon Joan M Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders
US20080166334A1 (en) * 2004-09-28 2008-07-10 Fallon Joan M Combination enzyme for cystic fibrosis
DE202008014562U1 (de) 2008-11-03 2009-02-26 Nordmark Arzneimittel Gmbh & Co. Kg Pankreatin
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US20090233344A1 (en) * 2008-03-11 2009-09-17 Nordmark Arzneimittel Gmbh & Co. Kg Pancreatin and method for reducing the viral and microbial contamination of pancreatin
US20090232789A1 (en) * 2008-03-13 2009-09-17 Fallon Joan M Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy
US20090324572A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of williams syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US20100169409A1 (en) * 2008-08-04 2010-07-01 Fallon Joan M Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain
US20100260857A1 (en) * 2009-04-13 2010-10-14 Joan Fallon Enzyme delivery systems and methods of preparation and use
WO2011035079A1 (en) 2009-09-17 2011-03-24 Eurand, Inc. Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US20110182818A1 (en) * 2008-07-01 2011-07-28 Fallon Joan M Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9259393B2 (en) 2000-11-15 2016-02-16 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413532C2 (ru) 2005-07-29 2011-03-10 Зольвай Фармасьютиклз Гмбх Способ получения стерилизованного порошкообразного панкреатина
UA98820C2 (ru) * 2007-11-15 2012-06-25 Солвей Фармасьютикалс Гмбх Способ отделения вирусной нагрузки от образца панкреатина
EP2165717A1 (de) * 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
AU2011228744A1 (en) * 2010-03-19 2012-10-11 Aptalis Pharma Canada Inc. Beta-propiolactone for inactivation of viruses in pharmaceutical pancreatic enzyme preparations
JP5814094B2 (ja) * 2011-11-30 2015-11-17 ふたみ青果株式会社 遠赤外線ヒーターによる凍結乾燥方法とその装置
ES2834483T3 (es) 2013-11-05 2021-06-17 Allergan Pharmaceuticals Int Ltd Composiciones farmacéuticas de pancreatina de alta potencia
MX2017005941A (es) * 2014-11-05 2018-02-13 Abbott Laboratories Gmbh Procesos para la producción de composiciones con perfil de seguridad mejorado teniendo actividad lipasa y composiciones adecuadas para medicamentos.
PL3298139T3 (pl) 2015-05-19 2022-01-31 Scientific Protein Laboratories Llc Sposób zmniejszenia lub inaktywacji zawartości wirusów i drobnoustrojów w sposobach wytwarzania pankreatyny
DE102015119006A1 (de) 2015-11-05 2017-05-11 Nordmark Arzneimittel Gmbh & Co. Kg Verfahren zur Reduzierung der Belastung von Pankreatin mit Mikroorganismen
US11278603B2 (en) 2016-03-28 2022-03-22 Abbvie Inc. Enzyme compositions with reduced viral and microbial contamination
BR112018070033A2 (pt) 2016-03-28 2019-02-05 Abbott Gmbh & Co Kg preparação enzimática, método para produzir um produto de pancreatina, composição farmacêutica e método para tratar insuficiência pancreática exócrina
KR101813920B1 (ko) * 2016-07-06 2018-01-04 넨시스(주) 판크레아틴의 살균방법 및 이를 이용한 판크레아틴 제조방법
EA202090851A1 (ru) 2017-09-27 2020-08-07 Эбботт Лэбораториз Гмбх Ферментные композиции со сниженным уровнем вирусного и микробного загрязнения

Citations (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324002A (en) * 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
US3950508A (en) * 1972-05-10 1976-04-13 Laboratoires Servier Process for obtaining pharmaceutical sustained releases
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US3986927A (en) * 1975-04-28 1976-10-19 Armour Pharmaceutical Company Process for the purification and sterilization of acidophilic biologicals by extreme acidification at cold temperatures
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
US4019958A (en) * 1975-03-22 1977-04-26 Kali-Chemie Pharma Gmbh Continuous process of producing pancreatin and product thereof
US4079125A (en) * 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions
US4106991A (en) * 1976-07-07 1978-08-15 Novo Industri A/S Enzyme granulate composition and process for forming enzyme granulates
US4280971A (en) * 1979-06-08 1981-07-28 Kali-Chemie Pharma Gmbh Process for the production of pancreatin pellets
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
US4533562A (en) * 1981-04-13 1985-08-06 Sankyo Company, Limited Method of preparing coated solid preparations
US4623624A (en) * 1982-12-30 1986-11-18 Basf Aktiengesellschaft Isolation of pancreatin
US4689297A (en) * 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US4929774A (en) * 1988-01-29 1990-05-29 Basf Aktiengesellschaft Stable mixture containing oxidation-sensitive compounds, preparation thereof and use of a combination of substances for stabilizing oxidation-sensitive compounds
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5300433A (en) * 1989-06-15 1994-04-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5324649A (en) * 1991-10-07 1994-06-28 Genencor International, Inc. Enzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereof
US5374657A (en) * 1991-01-24 1994-12-20 Martek Corporation Microbial oil mixtures and uses thereof
US5378462A (en) * 1992-08-19 1995-01-03 Kali-Chemie Pharma Gmbh Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding
US5489530A (en) * 1991-07-01 1996-02-06 Basf Aktiengesellschaft Lipase from Pseudomonas and strain
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5570104A (en) * 1993-02-24 1996-10-29 Sony Corporation Discharge chamber and method of manufacturing the same
US5614189A (en) * 1990-06-06 1997-03-25 Novo Nordisk A/S Recombinantly produced lipases for therapeutical treatment
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5658871A (en) * 1989-07-07 1997-08-19 Lever Brothers Company, Division Of Conopco, Inc. Microbial lipase muteins and detergent compositions comprising same
US5719115A (en) * 1993-07-05 1998-02-17 Henkel Kommanditgesellschaft Auf Aktien Coated enzyme preparation for detergents and cleaning formulations
US5725880A (en) * 1994-03-11 1998-03-10 Tanabe Seiyaku Co., Ltd. Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract
US5750148A (en) * 1994-08-19 1998-05-12 Shin-Etsu Chemical Co., Ltd. Method for preparing solid enteric pharmaceutical preparation
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5766912A (en) * 1986-03-17 1998-06-16 Novo Nordisk A/S Humicola lipase produced in aspergillus
US5783545A (en) * 1993-12-23 1998-07-21 Henkel Kommanditgesellschaft Auf Aktien Enzyme preparation containing a silver corrosion inhibitor
US5801022A (en) * 1990-08-03 1998-09-01 Vertex Pharmaceuticals, Incorporated Method of producing a product with crosslinked crystals of thermolysin
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5874558A (en) * 1986-03-17 1999-02-23 Novo Nordisk Nucleic acid encoding a recombinant humicola sp. lipase
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
US5993806A (en) * 1996-08-28 1999-11-30 Solvay Pharmaceuticals Gmbh Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
US6025391A (en) * 1996-04-12 2000-02-15 Novartis Ag Enteric-coated pharmaceutical compositions of mycophenolate
US6051220A (en) * 1995-05-31 2000-04-18 Medzyme N.V. And Simon Lodewijk Scharpe Composition to improve digestibility and utilization of nutrients
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US6224910B1 (en) * 1998-05-22 2001-05-01 Bristol-Myers Squibb Company Method for the preparation of an enteric coated high drug load pharmaceutical composition
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6278794B1 (en) * 1996-11-29 2001-08-21 Oxford Glycosciences (Uk) Ltd Computer-assisted isolation and characterization of proteins
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US6348442B2 (en) * 1998-06-30 2002-02-19 Novozymes A/S Enzyme containing granule
US6355461B2 (en) * 1996-04-29 2002-03-12 Novozymes A/S Non-aqueous, liquid, enzyme-containing compositions
US20020061302A1 (en) * 1999-03-17 2002-05-23 Suntje Sander-Struckmeier Method for the treatment of diabetes
US20020076438A1 (en) * 1998-05-22 2002-06-20 Ismat Ullah High drug load acid labile pharmaceutical composition
US6426091B1 (en) * 1997-09-30 2002-07-30 Nikken Chemicals Co., Ltd. Sustained-release theophylline tablet
US20020146451A1 (en) * 2000-07-15 2002-10-10 Sharma Virender K. Method for the administration of acid-labile drugs
US20030007962A1 (en) * 2001-05-23 2003-01-09 Vergez Juan A. Pharmaceutical composition containing mosapride and pancreatin
US20030049245A1 (en) * 2001-08-31 2003-03-13 Mann David M. Methods for sterilizing preparations of digestive enzymes
US20030086948A1 (en) * 2001-07-27 2003-05-08 Gattefosse S.A. Pharmaceutical composition for oral use comprising an active principle to undergo a large first intestinal passage effect
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US20030175259A1 (en) * 1998-03-09 2003-09-18 Hamper Karageozian Use of corneal hardening agents in enzymeorthokeratology
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040013697A1 (en) * 2000-05-30 2004-01-22 Gunther Berndl Self-emulsifying active substance formulation and use of this formulation
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20040033220A1 (en) * 2000-11-02 2004-02-19 Marcus Hartmann Use of enzymes obtained from ciliates as medicaments for promoting digestion
US20040057944A1 (en) * 2001-01-19 2004-03-25 Solvay Pharmaceuticals Gmbh Microbial enzyme mixtures useful to treat digestive disorders
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
US20040101562A1 (en) * 2000-11-15 2004-05-27 Mario Maio Microspheres of pancreatic enzymes with high stability and production method thereof
US6767729B1 (en) * 1999-05-27 2004-07-27 Amano Enzyme Inc. Enzyme liquor and process for producing the same enzyme preparation protease preparations and protease-producing bacterium
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US7211281B2 (en) * 1999-12-30 2007-05-01 Kemin Industries, Inc. Method for improving the activity of enzymes
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US7479378B2 (en) * 2003-07-29 2009-01-20 Solvay Pharmaceuticals Gmbh Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2189948A (en) 1938-10-31 1940-02-13 Griffith Laboratories Sterilization of pancreatin
US2503313A (en) 1947-04-14 1950-04-11 Levin Ezra Production of dried, defatted enzymatic material
DE2035739A1 (en) 1970-07-18 1972-01-27 Röhm FmbH, 6100 Darmstadt Oral enzyme prepsn - consisting of granulate with gastric juices-resistant coating in tablet or capsule form
JPS4936886A (zh) * 1972-08-15 1974-04-05
JPS5543723B2 (zh) 1972-08-24 1980-11-07
DE2410241A1 (de) 1974-03-04 1975-09-18 Christian Brunnengraeber Chem Granulataehnliche darreichungsform fuer arzneimittel
GB1603640A (en) 1977-07-20 1981-11-25 Gist Brocades Nv Enzyme particles
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
US4259440A (en) 1979-05-21 1981-03-31 Miles Laboratories, Inc. Hydrolysis and assay of triglycerides
JPS5855125B2 (ja) 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4495278A (en) 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
US4456590B2 (en) 1981-11-02 1989-05-30 Heat treatment of lyphilized blood clotting factor viii concentrate
JPS58148814A (ja) 1982-03-01 1983-09-05 Fujimoto Seiyaku Kk 消化酵素軟カプセル剤
JPS58179492A (ja) 1982-04-12 1983-10-20 Dainichi Seika Kogyo Kk 洗剤用酵素粒剤およびその製造方法
JPS59169491A (ja) 1983-03-15 1984-09-25 Duskin Franchise Co Ltd 酵素の安定化法
IE55711B1 (en) 1983-10-24 1990-12-19 Bausch & Lomb Improved method for enzymatic cleaning and disinfecting contact lenses
JPS61162185A (ja) 1985-01-09 1986-07-22 Nagase Seikagaku Kogyo Kk 顆粒状酵素製剤の製造方法
US4707287A (en) 1985-06-28 1987-11-17 The Procter & Gamble Company Dry bleach stable enzyme composition
JPH0622461B2 (ja) 1985-07-31 1994-03-30 キユーピー株式会社 水中油型乳化食品の製造方法
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
DE3764460D1 (de) 1986-05-21 1990-09-27 Novo Industri As Herstellung eines ein enzym enthaltenden granulates und dessen verwendung in reinigungsmitteln.
DE3642853A1 (de) 1986-12-16 1988-06-23 Ulrich Von Dr Ing Pidoll Arzneimittel
DK435687D0 (da) 1987-08-21 1987-08-21 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK435587D0 (da) 1987-08-21 1987-08-21 Novo Industri As Fremgangsmaade til fremstilling af et enzymholdigt granulat
ATE125865T1 (de) 1987-08-28 1995-08-15 Novo Nordisk As Rekombinante humicola-lipase und verfahren zur herstellung von rekombinanten humicola-lipasen.
WO1989008695A1 (en) 1988-03-14 1989-09-21 Novo-Nordisk A/S Stabilized particulate composition
DK78189D0 (da) 1989-02-20 1989-02-20 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK78089D0 (da) 1989-02-20 1989-02-20 Novo Industri As Detergentholdigt granulat og fremgangsmaade til fremstilling deraf
GB8915658D0 (en) 1989-07-07 1989-08-23 Unilever Plc Enzymes,their production and use
WO1991006638A1 (en) 1989-10-31 1991-05-16 Genencor International, Inc. Dust-free coated enzyme formulation
PH30058A (en) 1989-11-24 1996-11-08 Biochemie Gmbh Pancreation preparations
WO1991016060A1 (en) 1990-04-16 1991-10-31 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
JP3110437B2 (ja) 1990-05-17 2000-11-20 財団法人化学及血清療法研究所 流行性非ａ非ｂ型肝炎ウイルス抗原ペプチドおよびこれをコードする核酸断片
IE912767A1 (en) 1990-08-03 1992-02-12 Vertex Pharma Use of crosslinked crystals as a novel form of enzyme¹immobilization
JP3055799B2 (ja) 1990-11-21 2000-06-26 塩野義製薬株式会社 パンクレアチン含有組成物
US5254283A (en) 1991-01-17 1993-10-19 Genencor International, Inc. Isophthalic polymer coated particles
DK13491D0 (da) 1991-01-25 1991-01-25 Novo Nordisk As Anvendelse af et enzymholdigt granulat og fremgangsmaade til fremstilling af et forderstof i tabletform
DE4203315A1 (de) 1991-02-14 1992-08-20 Kali Chemie Pharma Gmbh Verfahren zur gewinnung von pankreatin
JP3312364B2 (ja) 1991-10-07 2002-08-05 ジェネンコア インターナショナル インコーポレーテッド 被覆した酵素含有顆粒
WO1993007260A1 (en) 1991-10-10 1993-04-15 Genencor International, Inc. Process for dust-free enzyme manufacture
DE4200002A1 (de) 1992-01-02 1993-07-08 Rudolf V Dipl Chem Dr Noronha Reinigungstablette fuer die zahnprothesen
US5686238A (en) 1992-02-10 1997-11-11 Baxter International Inc. Method and device for testing blood units for viral contamination
DK0713397T3 (da) 1992-03-24 2003-03-31 United Cancer Res Inst Vaccine indeholdende levende virus
WO1994008603A1 (en) 1992-10-16 1994-04-28 Smithkline Beecham Corporation Compositions
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
EP0719133A1 (en) 1993-09-15 1996-07-03 Unilever Plc Skin care method and composition
FR2710535B1 (fr) 1993-09-30 1995-11-24 Gattefosse Ets Sa Composition à usage pharmaceutique ou cosmétique apte à former une microémulsion.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE4422198C2 (de) 1994-06-24 1997-08-28 Audi Ag Verfahren zum Steuern der elektrischen Beheizung eines Katalysators
WO1996016151A1 (en) 1994-11-18 1996-05-30 Genencor International, Inc. Coated enzyme granules
JPH08143457A (ja) 1994-11-21 1996-06-04 Microbial Chem Res Found 酵素阻害剤および高脂血症抑制剤
CN1092236C (zh) 1995-05-29 2002-10-09 花王株式会社 含酶粒状物及其制备方法
JPH09125096A (ja) 1995-10-30 1997-05-13 Koei Sangyo:Kk 液状天然油脂洗剤
AU1200997A (en) 1995-12-22 1997-07-17 Helix Biotechnology Ltd Thermostable proteolytic enzyme from thermoactinomyces thalpophilus thm1
ATE291082T1 (de) 1996-04-12 2005-04-15 Novozymes As Enzymhaltige granulatkörner sowie verfahren zu deren herstellung
US6632648B1 (en) 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
CA2198317C (en) 1997-02-24 2003-01-07 Mouhsine El Abboudi Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof
AUPO693397A0 (en) 1997-05-22 1997-06-12 Betatene Limited Carotenoid formulation
NZ330940A (en) 1997-07-24 2000-02-28 F Production of consensus phytases from fungal origin using computer programmes
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
KR100387245B1 (ko) 1997-10-17 2003-08-19 일양약품주식회사 유산균의안정화를위한미세장용성코팅과립
JP2002512939A (ja) 1997-11-28 2002-05-08 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断および治療のためのツールとしての、リューマチ性関節炎の血清により認識されるシトルリン含有合成ペプチド
KR19990072826A (ko) 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US20030021844A1 (en) 1998-03-04 2003-01-30 Philippe Barthelemy Immediate-release oral pellet comprising polyglycolysed glycerides, and manufacturing process
FR2775597B1 (fr) 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
DE29824797U1 (de) 1998-05-22 2002-08-22 Bristol Myers Squibb Co Magensaftresistent überzogene Arzneimittel
DK1092007T3 (da) 1998-06-30 2004-04-05 Novozymes As Ny forbedret enzymholdig granule
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
DE19856415C2 (de) 1998-12-08 2001-06-07 Thomas Fenner Verfahren zur Reinigung bzw. Isolierung viraler Nukleinsäuren
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU7405400A (en) 1999-10-01 2001-05-10 Novozymes A/S Enzyme granulate
CN1171639C (zh) 1999-10-12 2004-10-20 第一三得利制药株式会社 口服药物组合物
CA2395343C (en) 2000-02-08 2009-06-30 F. Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
CN1336434A (zh) * 2000-08-01 2002-02-20 上海惠海生化制品厂 胰激肽原酶的制备及其亲和层析纯化方法
EP1317533A1 (en) 2000-09-08 2003-06-11 Novozymes A/S Lubricated granules
AU2001291647A1 (en) 2000-10-02 2002-04-15 Novozymes A/S Coated particles containing an active substance
ATE346590T1 (de) 2001-07-26 2006-12-15 Ethypharm Sa Umgehüllte allylamine oder benzylamine enthaltende granulate, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die umgehüllten granulate
US6783968B2 (en) * 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
HUP0501186A2 (en) 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
AU2002351749A1 (en) 2001-12-21 2003-07-15 Novozymes A/S Salt coatings
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
AU2003214037A1 (en) 2002-03-27 2003-10-08 Novozymes A/S Granules with filamentous coatings
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
JP2007506405A (ja) 2003-02-06 2007-03-22 ノボザイムス アクティーゼルスカブ 糸状菌におけるヒトｈ鎖抗体の発現
EP1711529A1 (en) 2004-01-21 2006-10-18 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
CN1946664B (zh) 2004-04-23 2012-08-15 出光兴产株式会社 镁化合物、用于烯烃聚合的催化剂和烯烃聚合物的制备方法
ITMI20040891A1 (it) 2004-05-04 2004-08-04 Ibsa Inst Biochimique Sa Nuovo metodo per la partizione ed inattivazione di contaminanti virali e prionici
EP1809320B1 (en) 2004-10-14 2010-07-21 Altus Pharmaceuticals Inc. Compositions containing lipase; protease and amylase for treating pancreatic insufficiency
AU2006261442A1 (en) 2005-06-24 2006-12-28 Novozymes A/S Lipases for pharmaceutical use
RU2413532C2 (ru) 2005-07-29 2011-03-10 Зольвай Фармасьютиклз Гмбх Способ получения стерилизованного порошкообразного панкреатина
US7951384B2 (en) 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
CN101242811B (zh) 2005-08-15 2015-06-17 雅培实验室有限公司 酸不稳定性药物的控释药物组合物
ATE418329T1 (de) 2005-08-15 2009-01-15 Solvay Pharm Gmbh Pankreatin-mikropellets geeignet für magensaftresistente überzüge
CA2653127C (en) 2006-05-22 2015-09-15 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
CN105112386A (zh) 2006-12-21 2015-12-02 诺维信公司 用于药物用途的脂肪酶变体
EP2079445B1 (en) 2007-02-20 2015-11-04 Aptalis Pharma Limited Stable digestive enzyme compositions

Patent Citations (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324002A (en) * 1962-09-17 1967-06-06 Armour Pharma Anti-inflammatory preparations containing proteolytic enzymes and adrenal glucocorticoids
US3803305A (en) * 1962-12-28 1974-04-09 Rolland A Lab Process for obtaining extracts from pancreas
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
US3950508A (en) * 1972-05-10 1976-04-13 Laboratoires Servier Process for obtaining pharmaceutical sustained releases
US4019958A (en) * 1975-03-22 1977-04-26 Kali-Chemie Pharma Gmbh Continuous process of producing pancreatin and product thereof
US3986927A (en) * 1975-04-28 1976-10-19 Armour Pharmaceutical Company Process for the purification and sterilization of acidophilic biologicals by extreme acidification at cold temperatures
US4079125A (en) * 1975-06-10 1978-03-14 Johnson & Johnson Preparation of enteric coated digestive enzyme compositions
US4106991A (en) * 1976-07-07 1978-08-15 Novo Industri A/S Enzyme granulate composition and process for forming enzyme granulates
US4280971A (en) * 1979-06-08 1981-07-28 Kali-Chemie Pharma Gmbh Process for the production of pancreatin pellets
US4533562A (en) * 1981-04-13 1985-08-06 Sankyo Company, Limited Method of preparing coated solid preparations
US4623624A (en) * 1982-12-30 1986-11-18 Basf Aktiengesellschaft Isolation of pancreatin
US4447412A (en) * 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4490361A (en) * 1983-12-02 1984-12-25 Alpha Therapeutic Corporation Virus inactivating heat treatment of plasma fractions
US4689297A (en) * 1985-03-05 1987-08-25 Miles Laboratories, Inc. Dust free particulate enzyme formulation
US4775536A (en) * 1986-02-24 1988-10-04 Bristol-Myers Company Enteric coated tablet and process for making
US5863759A (en) * 1986-03-17 1999-01-26 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5766912A (en) * 1986-03-17 1998-06-16 Novo Nordisk A/S Humicola lipase produced in aspergillus
US5874558A (en) * 1986-03-17 1999-02-23 Novo Nordisk Nucleic acid encoding a recombinant humicola sp. lipase
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US5536661A (en) * 1987-03-10 1996-07-16 Novo Nordisk A/S Process for the production of protein products in aspergillus
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US4929774A (en) * 1988-01-29 1990-05-29 Basf Aktiengesellschaft Stable mixture containing oxidation-sensitive compounds, preparation thereof and use of a combination of substances for stabilizing oxidation-sensitive compounds
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5300433A (en) * 1989-06-15 1994-04-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
US5658871A (en) * 1989-07-07 1997-08-19 Lever Brothers Company, Division Of Conopco, Inc. Microbial lipase muteins and detergent compositions comprising same
US6187572B1 (en) * 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5614189A (en) * 1990-06-06 1997-03-25 Novo Nordisk A/S Recombinantly produced lipases for therapeutical treatment
US6004768A (en) * 1990-08-03 1999-12-21 Vertex Pharmaceuticals, Inc. Biosensors, extracorporeal devices and methods for detecting substances using crosslinked protein crystals
US5801022A (en) * 1990-08-03 1998-09-01 Vertex Pharmaceuticals, Incorporated Method of producing a product with crosslinked crystals of thermolysin
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US6011001A (en) * 1990-08-03 2000-01-04 Vertex Pharmaceuticals, Inc. Method of protein therapy by orally administering crosslinked protein crystals
US5976529A (en) * 1990-08-03 1999-11-02 Vertex Pharmaceuticals, Inc. Methods of enzyme therapy by orally administering crosslinked enzyme crystals
US5849296A (en) * 1990-08-03 1998-12-15 Vertex Pharmaceuticals, Inc. Crosslinked protein crystals
US5869438A (en) * 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
US5374657A (en) * 1991-01-24 1994-12-20 Martek Corporation Microbial oil mixtures and uses thereof
US5489530A (en) * 1991-07-01 1996-02-06 Basf Aktiengesellschaft Lipase from Pseudomonas and strain
US5645832A (en) * 1991-07-01 1997-07-08 Basf Aktiengesellschaft Use of lipases for producing drugs
US6030798A (en) * 1991-07-01 2000-02-29 Basf Aktiengesellschaft Method of identifying a lipase for treatment of digestive disorders
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5324649A (en) * 1991-10-07 1994-06-28 Genencor International, Inc. Enzyme-containing granules coated with hydrolyzed polyvinyl alcohol or copolymer thereof
US5879920A (en) * 1991-10-07 1999-03-09 Genencor International, Inc. Coated enzyme-containing granule
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) * 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5378462A (en) * 1992-08-19 1995-01-03 Kali-Chemie Pharma Gmbh Pancreatin micropellets prepared with polyethylene glycol 4000, paraffin and a lower alcohol by extrusion and rounding
US5570104A (en) * 1993-02-24 1996-10-29 Sony Corporation Discharge chamber and method of manufacturing the same
US5719115A (en) * 1993-07-05 1998-02-17 Henkel Kommanditgesellschaft Auf Aktien Coated enzyme preparation for detergents and cleaning formulations
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5783545A (en) * 1993-12-23 1998-07-21 Henkel Kommanditgesellschaft Auf Aktien Enzyme preparation containing a silver corrosion inhibitor
US5725880A (en) * 1994-03-11 1998-03-10 Tanabe Seiyaku Co., Ltd. Pharmaceutical preparation controlled to release medicinal active ingredient at targeted site in intestinal tract
US5750148A (en) * 1994-08-19 1998-05-12 Shin-Etsu Chemical Co., Ltd. Method for preparing solid enteric pharmaceutical preparation
US6051220A (en) * 1995-05-31 2000-04-18 Medzyme N.V. And Simon Lodewijk Scharpe Composition to improve digestibility and utilization of nutrients
US6025391A (en) * 1996-04-12 2000-02-15 Novartis Ag Enteric-coated pharmaceutical compositions of mycophenolate
US6355461B2 (en) * 1996-04-29 2002-03-12 Novozymes A/S Non-aqueous, liquid, enzyme-containing compositions
US5750104A (en) * 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5993806A (en) * 1996-08-28 1999-11-30 Solvay Pharmaceuticals Gmbh Method of stabilizing pharmaceutical preparations comprising digestive enzyme mixtures
US6278794B1 (en) * 1996-11-29 2001-08-21 Oxford Glycosciences (Uk) Ltd Computer-assisted isolation and characterization of proteins
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US20030211127A1 (en) * 1997-04-11 2003-11-13 Margolin Alexey L. Controlled dissolution crosslinked prote in crystals
US20040202643A1 (en) * 1997-04-11 2004-10-14 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
US20020137156A1 (en) * 1997-04-11 2002-09-26 Alexey L. Margolin Controlled dissolution crosslinked protein crystals
US6426091B1 (en) * 1997-09-30 2002-07-30 Nikken Chemicals Co., Ltd. Sustained-release theophylline tablet
US20030175259A1 (en) * 1998-03-09 2003-09-18 Hamper Karageozian Use of corneal hardening agents in enzymeorthokeratology
US20020076438A1 (en) * 1998-05-22 2002-06-20 Ismat Ullah High drug load acid labile pharmaceutical composition
US6224910B1 (en) * 1998-05-22 2001-05-01 Bristol-Myers Squibb Company Method for the preparation of an enteric coated high drug load pharmaceutical composition
US6348442B2 (en) * 1998-06-30 2002-02-19 Novozymes A/S Enzyme containing granule
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US20020061302A1 (en) * 1999-03-17 2002-05-23 Suntje Sander-Struckmeier Method for the treatment of diabetes
US6767729B1 (en) * 1999-05-27 2004-07-27 Amano Enzyme Inc. Enzyme liquor and process for producing the same enzyme preparation protease preparations and protease-producing bacterium
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6734188B1 (en) * 1999-11-01 2004-05-11 John Rhodes Composition for treatment of constipation and irritable bowel syndrome
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7211281B2 (en) * 1999-12-30 2007-05-01 Kemin Industries, Inc. Method for improving the activity of enzymes
US20010046493A1 (en) * 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
US20030017144A1 (en) * 2000-02-24 2003-01-23 Altus Biologics Inc. Lipase-containing composition and methods of use thereof
US20040013697A1 (en) * 2000-05-30 2004-01-22 Gunther Berndl Self-emulsifying active substance formulation and use of this formulation
US20020146451A1 (en) * 2000-07-15 2002-10-10 Sharma Virender K. Method for the administration of acid-labile drugs
US20040033220A1 (en) * 2000-11-02 2004-02-19 Marcus Hartmann Use of enzymes obtained from ciliates as medicaments for promoting digestion
US20080292610A1 (en) * 2000-11-02 2008-11-27 Cilian Ag Medicaments containing enzymes from ciliates for promoting digestion in digestive disorders
US20040101562A1 (en) * 2000-11-15 2004-05-27 Mario Maio Microspheres of pancreatic enzymes with high stability and production method thereof
US20040057944A1 (en) * 2001-01-19 2004-03-25 Solvay Pharmaceuticals Gmbh Microbial enzyme mixtures useful to treat digestive disorders
US6692771B2 (en) * 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
US20030007962A1 (en) * 2001-05-23 2003-01-09 Vergez Juan A. Pharmaceutical composition containing mosapride and pancreatin
US20030086948A1 (en) * 2001-07-27 2003-05-08 Gattefosse S.A. Pharmaceutical composition for oral use comprising an active principle to undergo a large first intestinal passage effect
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US20030049245A1 (en) * 2001-08-31 2003-03-13 Mann David M. Methods for sterilizing preparations of digestive enzymes
US20040161423A1 (en) * 2002-07-18 2004-08-19 Sanjeev Kumar (Mendiratta) Polymer modified anti-angiogenic serpins
US20040213847A1 (en) * 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
US7479378B2 (en) * 2003-07-29 2009-01-20 Solvay Pharmaceuticals Gmbh Method of analyzing enzyme compositions with lipolytic, proteolytic and amylolytic activity
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations

Cited By (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040071683A1 (en) * 1999-12-17 2004-04-15 Fallon Joan M. Methods for treating pervasive development disorders
US8815233B2 (en) 1999-12-17 2014-08-26 Curemark Llc Method for treating pervasive development disorders
US8613918B2 (en) 1999-12-17 2013-12-24 Curemark Llc Method for treating pervasive development disorders
US8211661B2 (en) 1999-12-17 2012-07-03 Curemark, Llc Method for identifying individuals having a pervasive development disorder amenable to digestive enzyme therapy
US8163278B2 (en) 1999-12-17 2012-04-24 Curemark Llc Methods for treating pervasive development disorders
US9624526B2 (en) 1999-12-17 2017-04-18 Curemark Llc Method for treating pervasive development disorders
US9624525B2 (en) 1999-12-17 2017-04-18 Curemark, Llc Method for treating pervasive development disorders
US20090286270A1 (en) * 1999-12-17 2009-11-19 Fallon Joan M Method for treating pervasive development disorders
US8778335B2 (en) 2000-08-14 2014-07-15 Curemark, Llc Methods of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US9233146B2 (en) 2000-08-14 2016-01-12 Curemark, Llc Method of treating and diagnosing Parkinson's disease and related dysautonomic disorders
US20080152637A1 (en) * 2000-08-14 2008-06-26 Fallon Joan M Methods of treating and diagnosing parkinsons disease and related dysautonomic disorders
US9884025B2 (en) 2000-11-15 2018-02-06 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US9259393B2 (en) 2000-11-15 2016-02-16 Aptalis Pharma S.R.L. Microspheres of pancreatic enzymes with high stability and production method thereof
US8921054B2 (en) 2000-11-16 2014-12-30 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US9377459B2 (en) 2000-11-16 2016-06-28 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8580522B2 (en) 2000-11-16 2013-11-12 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US10209253B2 (en) 2000-11-16 2019-02-19 Curemark, Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20070270976A1 (en) * 2002-04-25 2007-11-22 Ultraflex Systems, Inc. Ambulating ankle & knee joints with bidirectional dampening and assistance using elastomeric restraint
US8802087B2 (en) 2004-03-22 2014-08-12 Abbott Products Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20050250817A1 (en) * 2004-03-22 2005-11-10 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions of lipase-containing products, in particular of pancreation
US20080166334A1 (en) * 2004-09-28 2008-07-10 Fallon Joan M Combination enzyme for cystic fibrosis
US20100233218A1 (en) * 2004-09-28 2010-09-16 Curemark Llc Combination enzyme for cystic fibrosis
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20070148153A1 (en) * 2005-08-15 2007-06-28 George Shlieout Controlled release pharmaceutical compositions for acid-labile drugs
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20070148152A1 (en) * 2005-08-15 2007-06-28 George Shlieout Process for the manufacture and use of pancreatin micropellet cores
US11033563B2 (en) 2005-08-30 2021-06-15 Curemark, Llc Use of lactulose in the treatment of autism
US10350229B2 (en) 2005-08-30 2019-07-16 Curemark, Llc Use of lactulose in the treatment of autism
US8673877B2 (en) 2005-08-30 2014-03-18 Curemark, Llc Use of lactulose in the treatment of autism
US9345721B2 (en) 2005-08-30 2016-05-24 Curemark, Llc Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20080019959A1 (en) * 2006-05-22 2008-01-24 Dietmar Becher Process for separating and determining the viral load in a pancreatin sample
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US10206882B2 (en) 2007-02-20 2019-02-19 Allergan Pharmaceuticals International Limited Stable digestive enzyme compositions
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US10087493B2 (en) * 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US20090226414A1 (en) * 2008-03-07 2009-09-10 Axcan Pharma Inc. Method for detecting infectious parvovirus in pharmaceutical preparations
US20090233344A1 (en) * 2008-03-11 2009-09-17 Nordmark Arzneimittel Gmbh & Co. Kg Pancreatin and method for reducing the viral and microbial contamination of pancreatin
US8283147B2 (en) 2008-03-11 2012-10-09 Nordmark Arzneimittel Gmbh & Co. Kg Pancreatin and method for reducing the viral and microbial contamination of pancreatin
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US9023344B2 (en) 2008-03-13 2015-05-05 Curemark, Llc Method of treating toxemia
US9925250B2 (en) 2008-03-13 2018-03-27 Curemark, Llc Method of treating proteinuria in pregnancy
US20090232789A1 (en) * 2008-03-13 2009-09-17 Fallon Joan M Novel pharmaceutical preparation for preeclampsia, eclampsia, and toxemia, and their related symptoms and related disorders of pregnancy
US9408895B2 (en) 2008-03-13 2016-08-09 Curemark, Llc Method of treating pregnancy-induced hypertension
US11045527B2 (en) 2008-03-13 2021-06-29 Curemark, Llc Method of diagnosing preeclampsia or pregnancy-induced hypertension
US10272141B2 (en) 2008-04-18 2019-04-30 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8486390B2 (en) 2008-04-18 2013-07-16 Curemark Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US8318158B2 (en) 2008-04-18 2012-11-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9017665B2 (en) 2008-04-18 2015-04-28 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US11235038B2 (en) 2008-04-18 2022-02-01 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9687534B2 (en) 2008-04-18 2017-06-27 Curemark, Llc Pharmaceutical preparation for the treatment of the symptoms of addiction and method of diagnosing same
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US10588948B2 (en) 2008-06-26 2020-03-17 Curemark, Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US20090324572A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of williams syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20110182818A1 (en) * 2008-07-01 2011-07-28 Fallon Joan M Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US20100169409A1 (en) * 2008-08-04 2010-07-01 Fallon Joan M Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of parkinsons disease, movement and neurological disorders, and chronic pain
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US9687535B2 (en) 2008-10-03 2017-06-27 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
US9061033B2 (en) 2008-10-03 2015-06-23 Curemark Llc Methods and compositions for the treatment of symptoms of prion diseases
US10413601B2 (en) 2008-10-03 2019-09-17 Curemark, Llc Methods and compositions for the treatment of symptoms of prion diseases
DE202008014562U1 (de) 2008-11-03 2009-02-26 Nordmark Arzneimittel Gmbh & Co. Kg Pankreatin
US9107419B2 (en) 2009-01-06 2015-08-18 Curelon Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US10736946B2 (en) 2009-01-06 2020-08-11 Galenagen, Llc Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
US9895427B2 (en) 2009-01-06 2018-02-20 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US11357835B2 (en) 2009-01-06 2022-06-14 Galenagen, Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US20100260857A1 (en) * 2009-04-13 2010-10-14 Joan Fallon Enzyme delivery systems and methods of preparation and use
US9931302B2 (en) 2009-04-13 2018-04-03 Curemark , LLC Enzyme delivery systems and methods of preparation and use
US11419821B2 (en) 2009-04-13 2022-08-23 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US10098844B2 (en) 2009-04-13 2018-10-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
US9415014B2 (en) 2009-04-13 2016-08-16 Curemark, Llc Enzyme delivery systems and methods of preparation and use
WO2011035079A1 (en) 2009-09-17 2011-03-24 Eurand, Inc. Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US10716835B2 (en) 2009-10-21 2020-07-21 Curemark, Llc Methods and compositions for the prevention and treatment of influenza
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US11364205B2 (en) 2010-10-01 2022-06-21 Societe Des Produits Nestle S.A. Stable low digestive enzyme content formulation
US10940187B2 (en) 2011-04-21 2021-03-09 Curemark, Llc Method of treatment of schizophreniform disorder
US9492515B2 (en) 2011-04-21 2016-11-15 Curemark, Llc Method of treatment of schizophreniform disorder
US10279016B2 (en) 2011-04-21 2019-05-07 Curemark, Llc Method of treatment of schizophreniform disorder
US8980252B2 (en) 2011-04-21 2015-03-17 Curemark Llc Methods of treatment of schizophrenia
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US11364287B2 (en) 2012-05-30 2022-06-21 Curemark, Llc Methods of treating celiac disease
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US10184121B2 (en) 2013-06-28 2019-01-22 Allergan Pharmaceuticals International Limited Methods for removing viral contaminants from pancreatic extracts
US10993996B2 (en) 2013-08-09 2021-05-04 Allergan Pharmaceuticals International Limited Digestive enzyme composition suitable for enteral administration
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Also Published As

Publication number Publication date
HUE031042T2 (en) 2017-06-28
CN101233229B (zh) 2013-05-01
WO2007014896A1 (en) 2007-02-08
AU2006274835A1 (en) 2007-02-08
RU2008107261A (ru) 2009-09-10
JP2009502876A (ja) 2009-01-29
NO340996B1 (no) 2017-07-31
EP2278002A1 (en) 2011-01-26
UA93384C2 (ru) 2011-02-10
RU2413532C2 (ru) 2011-03-10
NO20171131A1 (no) 2008-04-28
EP1913138B1 (en) 2016-08-24
KR20080036622A (ko) 2008-04-28
US10704037B2 (en) 2020-07-07
KR101555058B1 (ko) 2015-09-22
ES2597381T3 (es) 2017-01-18
US20200299669A1 (en) 2020-09-24
CA2616943A1 (en) 2007-02-08
CA2616943C (en) 2016-04-12
CN101233229A (zh) 2008-07-30
AU2006274835B2 (en) 2012-05-24
NO20081087L (no) 2008-04-28
JP5140586B2 (ja) 2013-02-06
ES2635308T3 (es) 2017-10-03
EP1913138A1 (en) 2008-04-23
IL189103A (en) 2012-03-29
US20170073660A1 (en) 2017-03-16
BRPI0614914A2 (pt) 2011-04-19
HUE034739T2 (en) 2018-02-28
HK1120288A1 (en) 2009-03-27
MX2008000850A (es) 2008-03-18
EP2278002B1 (en) 2017-07-12
NO342419B1 (no) 2018-05-22
PL1913138T3 (pl) 2017-07-31
IL189103A0 (en) 2008-08-07
PL2278002T3 (pl) 2017-12-29

Similar Documents

Publication Publication Date Title
US20200299669A1 (en) Processes for the Manufacture and Use of Pancreatin
ES2385958T3 (es) Procedimiento para reducir la carga viral y microbiana de pancreatina
TR201808840T4 (tr) Stabil sindirim enzimi bileşimleri.
AU2015275860A1 (en) Methods for removing viral contaminants from pancreatic extracts
US20190201502A1 (en) Enzyme compositions with reduced viral and microbial contamination
US9107966B2 (en) Method for reducing the viral and microbial load of biological extracts containing solids
US20220211825A1 (en) Enzyme compositions with reduced viral and microbial contamination
CN111630164A (zh) 具有减少的病毒和微生物污染的酶组合物
EA045569B1 (ru) Ферментный препарат со сниженным уровнем вирусного и микробного загрязнения и способ его получения
EA045327B1 (ru) Композиции ферментов с уменьшенным вирусным и микробным загрязнением
EA040925B1 (ru) Препарат панкреатина с уменьшенной вирусной и микробной нагрузкой и способ его получения

Legal Events

Date Code Title Description
AS Assignment

Owner name: SOLVAY PHARMACEUTICALS GMBH, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FRINK, MARTIN;KOELLN, CLAUS-JUERGEN;BLUME, HEINZ;AND OTHERS;REEL/FRAME:018954/0313;SIGNING DATES FROM 20070206 TO 20070215

AS Assignment

Owner name: ABBOTT PRODUCTS GMBH, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SOLVAY PHARMACEUTICALS GMBH;REEL/FRAME:027408/0558

Effective date: 20100325

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION